CHICAGO–(ENEWSPF)–April 23, 2015. Roosevelt PharmD students Bradley McAllister and Trusha Mistry (pictured above) recently tested the theory that simultaneous inhibition of multiple kinases can provide synergistic effects on tumor growth and resistance, sharing their findings during a poster presentation during the 7th annual Yao-Yuan Pharma Biotech symposium held April 18 in Chicago.
Members of the College of Pharmacy’s 2016 graduating class, McAllister and Mistry found that resistance against approved kinase inhibitors targeting the epidermal growth factor receptor (EGFR) kinase could be overcome if given in combination with the aurora kinase A (AURKA) inhibitors.
Under the direction of Roosevelt Assistant Professor of Medicinal Chemistry Sonali Kurup, the students identified the 4-anilinosubstitutedpyrrolo[2,3-d]pyrimidine scaffold as a dual inhibitor of EGFR and AURKA. Compound 1, N4-(3-bromophenyl)pyrrolo[2,3-d]pyrimidin-4-amine was the best in the series with nanomolar inhibition of EGFR and single-digit micromolar inhibition of AURKA. The compounds demonstrated moderate inhibition of lung cancer and colon cancer cells.
Source: www.roosevelt.edu
